New drug cocktail shows promise for rare blood cancer
NCT ID NCT03623373
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of four drugs (acalabrutinib, bendamustine, rituximab, and cytarabine) as a first treatment for people with mantle cell lymphoma, a rare blood cancer. The goal was to see if this approach could safely improve remission rates before a stem cell transplant. The study included 13 adults aged 18 to 70 who were eligible for transplant. The results may help design larger trials to find a better standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- acalabrutinib, bendamustine, rituximab, cytarabine
- What this could lead to
- If this combination works well, it could become a standard first treatment for mantle cell lymphoma, helping more patients achieve remission before a stem cell transplant.
- What could go wrong
- This was a very small pilot study with only 13 people. Larger studies are needed to confirm safety and effectiveness. The drugs can cause serious side effects like infections and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Smartwatches track hidden heart risk in blood cancer patients